{"title":"氯吡格雷与血小板功能检测的药理学研究:临床影响","authors":"A. Almeman, H. Khalaf","doi":"10.4172/2155-9864.1000334","DOIUrl":null,"url":null,"abstract":"Cytochrome 450 (CYP 450) 2C19 is a well known polymorphic metabolising enzyme which is responsible for converting clopidogrel to its active form [1]. Measuring the resulting activity based on Platelet Reactivity Units (PRU) or inhibition rates of the platelet is well correlated with the genetic polymorphism in several studies worldwide [1-3]. However, the debate is whether the polymorphism or PRU may result in any significant clinical endpoint.","PeriodicalId":182392,"journal":{"name":"Journal of Blood Disorders and Transfusion","volume":"4 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2016-01-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Pharmacogenetic of Clopidogrel and Platelet Function Testing: The Clinical Impact\",\"authors\":\"A. Almeman, H. Khalaf\",\"doi\":\"10.4172/2155-9864.1000334\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Cytochrome 450 (CYP 450) 2C19 is a well known polymorphic metabolising enzyme which is responsible for converting clopidogrel to its active form [1]. Measuring the resulting activity based on Platelet Reactivity Units (PRU) or inhibition rates of the platelet is well correlated with the genetic polymorphism in several studies worldwide [1-3]. However, the debate is whether the polymorphism or PRU may result in any significant clinical endpoint.\",\"PeriodicalId\":182392,\"journal\":{\"name\":\"Journal of Blood Disorders and Transfusion\",\"volume\":\"4 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2016-01-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Blood Disorders and Transfusion\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4172/2155-9864.1000334\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Blood Disorders and Transfusion","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4172/2155-9864.1000334","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Pharmacogenetic of Clopidogrel and Platelet Function Testing: The Clinical Impact
Cytochrome 450 (CYP 450) 2C19 is a well known polymorphic metabolising enzyme which is responsible for converting clopidogrel to its active form [1]. Measuring the resulting activity based on Platelet Reactivity Units (PRU) or inhibition rates of the platelet is well correlated with the genetic polymorphism in several studies worldwide [1-3]. However, the debate is whether the polymorphism or PRU may result in any significant clinical endpoint.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
